Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000308808 represents a novel, uncharacterized long non-coding RNA that is transcribed antisense to the TPBGL gene locus. It is not a protein-coding gene and lacks known biological function, disease association, molecular classification beyond "lncRNA," and clinical relevance. None of the available databases assign it a canonical name apart from its generic annotation, and there are no established aliases, functional annotations, or drugs associated with this RNA transcript. Its existence is supported only by genomic prediction and annotation, not by experimental characterization or clinical use[1][4]. In summary, ENSG00000308808 is a provisionally annotated lncRNA, not recognized as a therapeutic target, and currently lacks functional or clinical annotation[1][4].
No mechanisms of action reported; not a target for existing drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to TPBGL (ENSG00000308808).